<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="bold;} span.year {font-family : courier ; font-style : italic;} Eur" exact="Heart" post="J Cardiovasc PharmacotherEur Heart J Cardiovasc PharmacotherehjcvpEuropean Heart Journal"/>
 <result pre="courier ; font-style : italic;} Eur Heart J Cardiovasc PharmacotherEur" exact="Heart" post="J Cardiovasc PharmacotherehjcvpEuropean Heart Journal â€&quot; Cardiovascular Pharmacotherapy2055-68372055-6845Oxford University"/>
 <result pre="italic;} Eur Heart J Cardiovasc PharmacotherEur Heart J Cardiovasc PharmacotherehjcvpEuropean" exact="Heart" post="Journal â€&quot; Cardiovascular Pharmacotherapy2055-68372055-6845Oxford University Press pmcid: 7314063 pmid:"/>
 <result pre="Microbiology and System Biology, Netherlands Organisation for Applied Scientific ResearchNetherlands[p2]," exact="Vascular" post="Medicine, Amsterdam UMC, Academic Medical Center AmsterdamNetherlands[p3], Clinical Epidemiology,"/>
 <result pre="on a solid theoretical understanding of the mechanisms of SARS-CoV-2" exact="infection" post="and host responses, which is coupled to the practical"/>
 <result pre="was found to enter the cell only by angiotensin II" exact="type 1" post="receptor (AT1R)-induced endocytosis, after which ACE2 is destroyed. This"/>
 <result pre="immune regulatory mechanisms. The proposed mechanism by which SARS-CoV-2 causes" exact="disease" post="immediately suggests a possible treatment, since the AT1R is"/>
 <result pre="March 2020, the World Health Organizaton (WHO) declared the coronavirus" exact="disease" post="COVID-19 outbreak to have evolved to a pandemic, once"/>
 <result pre="must be swift, and conclusions must be drawn from the" exact="limited" post="knowledge at hand, acting on everything that has been"/>
 <result pre="that may bear similar characteristics. Human coronaviruses cause âˆ¼30% of" exact="upper" post="respiratory tract infections but are rarely lethal. Occasionally, however,"/>
 <result pre="may bear similar characteristics. Human coronaviruses cause âˆ¼30% of upper" exact="respiratory" post="tract infections but are rarely lethal. Occasionally, however, some"/>
 <result pre="similar characteristics. Human coronaviruses cause âˆ¼30% of upper respiratory tract" exact="infections" post="but are rarely lethal. Occasionally, however, some strains emerge"/>
 <result pre="that are life-threatening, having caused past epidemics such as severe" exact="acute" post="respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS),"/>
 <result pre="are life-threatening, having caused past epidemics such as severe acute" exact="respiratory" post="syndrome (SARS) and Middle East respiratory syndrome (MERS), as"/>
 <result pre="life-threatening, having caused past epidemics such as severe acute respiratory" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS), as well"/>
 <result pre="such as severe acute respiratory syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS), as well as the current emerging SARS-CoV-2"/>
 <result pre="as severe acute respiratory syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS), as well as the current emerging SARS-CoV-2 pandemic."/>
 <result pre="found to enter the cell only via angiotensin II (AngII)" exact="type 1" post="receptor (AT1R)-induced endocytosis, after which ACE2 is destroyed. Since"/>
 <result pre="plays an important role in maintaining key biological processes, the" exact="deficiency" post="of this enzyme may have severe consequences. Translational perspective"/>
 <result pre="ACE2 deficiency, which disrupts immune regulatory mechanisms. Since angiotensin II" exact="type 1" post="receptor (AT1R) appears to facilitate entry of SARS-CoV-2 into"/>
 <result pre="cases of SARS-CoV-2 infection, a larger number of individuals had" exact="hypertension" post="and diabetes.2â€&quot;5 A recent report in the Journal of"/>
 <result pre="laboratory-confirmed COVID-19 infections, from Wuhan China, that found more severe" exact="disease" post="outcomes in patients with hypertension, coronary artery disease, diabetes,"/>
 <result pre="that found more severe disease outcomes in patients with hypertension," exact="coronary artery disease," post="diabetes, and chronic renal disease. This suggested that, since"/>
 <result pre="found more severe disease outcomes in patients with hypertension, coronary" exact="artery disease," post="diabetes, and chronic renal disease. This suggested that, since"/>
 <result pre="outcomes in patients with hypertension, coronary artery disease, diabetes, and" exact="chronic" post="renal disease. This suggested that, since all the patients"/>
 <result pre="in patients with hypertension, coronary artery disease, diabetes, and chronic" exact="renal disease." post="This suggested that, since all the patients with such"/>
 <result pre="assumes that increased levels of ACE2 are associated with increased" exact="viral" post="uptake. Considering the fact that ACE2 acts outside the"/>
 <result pre="expression of ACE2 may very well be inversely related to" exact="viral" post="uptake. Also, Danser et al. explain that there are"/>
 <result pre="in patients treated with an ARB, might confer potential protective" exact="pulmonary" post="and cardiovascular effects. In the New England Journal of"/>
 <result pre="treated with an ARB, might confer potential protective pulmonary and" exact="cardiovascular" post="effects. In the New England Journal of Medicine, Vaduganathan"/>
 <result pre="ACE2 functions and that it has been postulated that ACE2" exact="deficiency" post="induces unabated AngII activity, which may be in part"/>
 <result pre="has proinflammatory, proliferative, and profibrotic functions that are beneficial during" exact="infection" post="and hypoxia but are deleterious if present in a"/>
 <result pre="proliferative, and profibrotic functions that are beneficial during infection and" exact="hypoxia" post="but are deleterious if present in a healthy person"/>
 <result pre="or in the case of prolonged activation during disease.10 During" exact="pulmonary" post="infection, AngII induces pulmonary vasoconstriction and vascular permeability, which"/>
 <result pre="of prolonged activation during disease.10 During pulmonary infection, AngII induces" exact="pulmonary" post="vasoconstriction and vascular permeability, which reduces hypoxia and facilitates"/>
 <result pre="during disease.10 During pulmonary infection, AngII induces pulmonary vasoconstriction and" exact="vascular" post="permeability, which reduces hypoxia and facilitates extravasation of cytokines"/>
 <result pre="infection, AngII induces pulmonary vasoconstriction and vascular permeability, which reduces" exact="hypoxia" post="and facilitates extravasation of cytokines to the site of"/>
 <result pre="inflammation, respectively. This inflammatory response, if exacerbated, causes oedema and" exact="respiratory" post="distress. ACE2 is mainly located at and bound to"/>
 <result pre="a healthy equilibrium, rather than an exacerbation of inflammation, a" exact="complete" post="description of the regulatory mechanisms is still lacking. Figure"/>
 <result pre="of coronaviruses are known. and Jia et al. found that" exact="infection" post="of human airway epithelia with SARS coronavirus correlated with"/>
 <result pre="molecular signals that cause the ongoing induction of AngII during" exact="infection" post="with SARS-CoV-2. The function of the RAS in the"/>
 <result pre="The function of the RAS in the immune response to" exact="infections" post="Upon infection by a previously unencountered virus, the initial"/>
 <result pre="of the RAS in the immune response to infections Upon" exact="infection" post="by a previously unencountered virus, the initial immune response"/>
 <result pre="nitric oxide (NO), which results in a marked inflammatory reaction.19" exact="Absence of" post="NO induces vasoconstriction and increased vascular permeability, which prevents"/>
 <result pre="marked inflammatory reaction.19 Absence of NO induces vasoconstriction and increased" exact="vascular" post="permeability, which prevents hypoxia and facilitates the entrance of"/>
 <result pre="of NO induces vasoconstriction and increased vascular permeability, which prevents" exact="hypoxia" post="and facilitates the entrance of cytokines to sites of"/>
 <result pre="for destruction may be considered an alternative strategy to limit" exact="viral" post="load.14 However, if a specific pH is reached, the"/>
 <result pre="viral load.14 However, if a specific pH is reached, the" exact="viral" post="envelope may fuse with the endosome before reaching the"/>
 <result pre="the lysosomes, NO is produced,24 which is thought to reduce" exact="viral" post="replication25 and initiate a virus-specific immune response.26 This lysosomal"/>
 <result pre="of the adaptive immune response. During inflammation and in the" exact="absence of" post="NO, AngII activates the AT1R. AT1R induces cellular uptake"/>
 <result pre="induces cellular uptake of ACE2-bound SARS-CoV-2. Inhibition of AT1R inhibits" exact="viral" post="uptake and facilitates AT2R-induced ACE2 expression and subsequent activation"/>
 <result pre="(ONOOâ€&quot;),29 which is unable to prevent ACE2 uptake. In the" exact="absence of" post="NO, AngII favours the AT1R pathway,30 which in turn"/>
 <result pre="infection, AT1R-mediated ACE2 destruction plays a deleterious role, promoting both" exact="viral" post="uptake and AngII-induced inflammation. Destruction of NO by superoxide"/>
 <result pre="of these organs. It has been shown that the SARS-CoV-2" exact="infection" post="was related to active myocardial injury, myocardial stress, and"/>
 <result pre="infection was related to active myocardial injury, myocardial stress, and" exact="cardiomyopathy" post="during the course of illness.32 Additionally, âˆ¼25% occurrence of"/>
 <result pre="cardiomyopathy during the course of illness.32 Additionally, âˆ¼25% occurrence of" exact="acute" post="kidney injury (AKI) has been reported in several clinical"/>
 <result pre="during the course of illness.32 Additionally, âˆ¼25% occurrence of acute" exact="kidney injury" post="(AKI) has been reported in several clinical settings.33,34 As"/>
 <result pre="and fibrinolysis, explaining the observed higher values of D-dimer and" exact="cardiovascular" post="thrombotic events.35 Treating SARS-CoV-2 infection with AT1R antagonists Following"/>
 <result pre="higher values of D-dimer and cardiovascular thrombotic events.35 Treating SARS-CoV-2" exact="infection" post="with AT1R antagonists Following the above, SARS-CoV-2 infection by"/>
 <result pre="Treating SARS-CoV-2 infection with AT1R antagonists Following the above, SARS-CoV-2" exact="infection" post="by binding to ACE2 disrupts the normal AngII:ACE2 balance,"/>
 <result pre="lung, which mediate the release of cytokines and contribute to" exact="acute" post="lung injury.36 Since the most important mechanism leading to"/>
 <result pre="Since the most important mechanism leading to pathology is the" exact="uncontrolled" post="AngII activity, leading to increased activation of AT1R which"/>
 <result pre="increased activation of AT1R which appears to be involved in" exact="viral" post="uptake, treatment actions should be aimed at preventing or"/>
 <result pre="be expected that treatment with AT1R inhibitors (ARBs) might limit" exact="viral" post="uptake and preserve ACE2 functions. On the other hand,"/>
 <result pre="treatment effect will probably depend on the phase of the" exact="disease" post="in which the treatment is initiated. In the early"/>
 <result pre="the SARS-CoV-2 infection, by restoring ACE2 function and thereby preventing" exact="viral" post="load accumulation. On the other hand, when the disease"/>
 <result pre="preventing viral load accumulation. On the other hand, when the" exact="disease" post="reaches the â€˜point of no returnâ€™, when viral replication"/>
 <result pre="when the disease reaches the â€˜point of no returnâ€™, when" exact="viral" post="replication has exhausted cellular metabolites and the inflammatory response"/>
 <result pre="the proinflammatory role of AngII and its permissive function in" exact="viral" post="uptake in COVID-19 and the anti-inflammatory effect of ACE2,"/>
 <result pre="and the anti-inflammatory effect of ACE2, treatment should ideally prevent" exact="viral" post="uptake and replication, while preserving ACE2 functions. Chloroquine The"/>
 <result pre="al. found that chloroquine was effective in preventing or diminishing" exact="viral" post="uptake shortly after infection, by preventing SARS-CoV-2 from binding"/>
 <result pre="which would impair tissues in responding to hypoxia, damage, or" exact="infection" post="by increasing AngII. Antiviral drugs Antiviral drugs may disrupt"/>
 <result pre="by increasing AngII. Antiviral drugs Antiviral drugs may disrupt the" exact="viral" post="life cycle at different stages. Some disrupt the synthesis"/>
 <result pre="life cycle at different stages. Some disrupt the synthesis of" exact="viral" post="proteins and nucleic acids. Other antiviral drugs inhibit virus"/>
 <result pre="drugs that are being used in the treatment of the" exact="infection" post="are the class that prevents viral replication inside the"/>
 <result pre="the treatment of the infection are the class that prevents" exact="viral" post="replication inside the cell after the SARS-CoV-2â€&quot;ACE2 complex has"/>
 <result pre="endocytosed. To our knowledge, no antiviral drugs exist that decrease" exact="viral" post="load without interfering with ACE2. Immunomodulating therapies Several immunomodulating"/>
 <result pre="with these drugs are the severe side effects, of which" exact="secondary" post="infections are the most important. In addition, these treatment"/>
 <result pre="these drugs are the severe side effects, of which secondary" exact="infections" post="are the most important. In addition, these treatment options"/>
 <result pre="antagonist compared with usual care or placebo. Considering the proposed" exact="disease" post="mechanism in which increasing AngII levels induce increased viral"/>
 <result pre="proposed disease mechanism in which increasing AngII levels induce increased" exact="viral" post="uptake, we believe that the treatment will be most"/>
 <result pre="placebo-controlled randomized Losartan 25 mg o.d. Placebo Non-hospitalized Proven SARS-CoV-2" exact="infection" post="Cough, rhinorrhea, or fever Admission to hospital 580 Yes"/>
 <result pre="placebo-controlled randomized Losartan 50 mg o.d. Placebo Hospitalized Proven SARS-CoV-2" exact="infection" post="Respiratory failure Difference in estimated (PEEP adjusted) P/F ratio"/>
 <result pre="randomized Losartan 50 mg o.d. Placebo Hospitalized Proven SARS-CoV-2 infection" exact="Respiratory" post="failure Difference in estimated (PEEP adjusted) P/F ratio at"/>
 <result pre="50 mg o.d. day 3 Standard care Hospitalized Proven SARS-CoV-2" exact="infection" post="Respiratory failure Adverse event due to losartan 50 Yes"/>
 <result pre="mg o.d. day 3 Standard care Hospitalized Proven SARS-CoV-2 infection" exact="Respiratory" post="failure Adverse event due to losartan 50 Yes NCT04343001"/>
 <result pre="mg/asprin 150 mg/simvastatin 80 mg o.d. Comparison Hospitalized Suspected SARS-CoV-2" exact="infection" post="Fever, cough, hypoxia 28 day death 10 000 No"/>
 <result pre="80 mg o.d. Comparison Hospitalized Suspected SARS-CoV-2 infection Fever, cough," exact="hypoxia" post="28 day death 10 000 No NCT04328012 Bassett Healthcare"/>
 <result pre="randomized comparison Losartan 25 mg o.d. Placebo Hospitalized Proven SARS-CoV-2" exact="infection" post="NCOSS scores 4000 Yes NCT04340557 Sharp HealthCare Multicentre open"/>
 <result pre="randomized Losartan 12.5 mg t.i.d Standard care Hospitalized Proven SARS-CoV-2" exact="infection" post="Requiring oxygen ICU admission for mechanical ventilation 200 Yes"/>
 <result pre="trial, factorial, randomized Losartan 25 mg o.d. Comparison Proven SARS-CoV-2" exact="infection" post="Improvement in FMTVDM measurement with nuclear imaging. 500 Enrolling"/>
 <result pre="randomized Candesartan 4 mg o.d. Standard care Hospitalized Proven SARS-CoV-2" exact="infection" post="Sustained improvement (&amp;gt;48 h) of one point on the"/>
 <result pre="randomized Telmisartan 80 mg t.d. Standard care Hospitalized Proven SARS-CoV-2" exact="infection" post="Need for supplementary oxygen 400 Yes NCT04335786 Radboud University"/>
 <result pre="titrated up to 160 mg o.d. Placebo Hospitalized Proven SARS-CoV-2" exact="infection" post="Admission to the ICU for mechanical ventilation or death"/>
 <result pre="randomized Telmisartan 20 mg o.d. Vitamin complex Non-hospitalized Proven SARS-CoV-2" exact="infection" post="Age â‰¥ 65 years Proportion of participants with an"/>
 <result pre="Ordinal Severity Scale scores; FMTVDM, Fleming method for tissue and" exact="vascular" post="differentiation and metabolism; t.d., twice a day. Conclusion Because"/>
 <result pre="SARS-CoV-2 enters the cell bound to ACE2, which induces ACE2" exact="deficiency" post="at the cell membrane, AngII is persistently activated. Increased"/>
 <result pre="ACE2 deficiency at the cell membrane, AngII is persistently activated." exact="Increased" post="AngII induces activation of AT1R, causing more uptake of"/>
 <result pre="This non-specific immune response is an attempt to reduce the" exact="viral" post="load, while the specific immune response is mounted. Unrestrained"/>
 <result pre="immune response is mounted. Unrestrained AngII eventually causes death by" exact="respiratory" post="distress induced by excessive inflammation and its deleterious effects"/>
 <result pre="increased AngII induces endocytosis of ACE2-bound SARS-CoV-2, leading to ACE2" exact="deficiency" post="and viral replication; (ii) ACE2 deficiency prevents the priming"/>
 <result pre="induces endocytosis of ACE2-bound SARS-CoV-2, leading to ACE2 deficiency and" exact="viral" post="replication; (ii) ACE2 deficiency prevents the priming of an"/>
 <result pre="SARS-CoV-2, leading to ACE2 deficiency and viral replication; (ii) ACE2" exact="deficiency" post="prevents the priming of an adaptive immune response by"/>
 <result pre="of NO; and (iii) Ang II induces an increase in" exact="viral" post="load leading to an increased innate immune response and"/>
 <result pre="for the illustrations. References References 1FangL, KarakiulakisG, RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
 <result pre="illustrations. References References 1FangL, KarakiulakisG, RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir Med2020;8:e21.32171062 2GuanWJ,"/>
 <result pre="Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med2020;382:1708â€&quot;1720.32109013 3HuangC, WangY,"/>
 <result pre="PengZ.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, China. JAMA2020;doi: 10.1001/jama.2020.1585. 5ZhangJJ, DongX, CaoYY, YuanYD,"/>
 <result pre="7DeshotelsMR, XiaH, SriramulaS, LazartiguesE, FilipeanuCM.Angiotensin II mediates angiotensin converting enzyme" exact="type 2" post="internalization and degradation through an angiotensin II type I"/>
 <result pre="enzyme type 2 internalization and degradation through an angiotensin II" exact="type I" post="receptor-dependent mechanism. Hypertension2014;64:1368â€&quot;1375.25225202 8DanserAHJ, EpsteinM, BatlleD.Reninâ€&quot;angiotensin system blockers and"/>
 <result pre="PeweL, NetlandJ, FarzanM, Wohlford-LenaneC, PerlmanS, McCrayPBJr.ACE2 receptor expression and severe" exact="acute" post="respiratory syndrome coronavirus infection depend on differentiation of human"/>
 <result pre="NetlandJ, FarzanM, Wohlford-LenaneC, PerlmanS, McCrayPBJr.ACE2 receptor expression and severe acute" exact="respiratory" post="syndrome coronavirus infection depend on differentiation of human airway"/>
 <result pre="FarzanM, Wohlford-LenaneC, PerlmanS, McCrayPBJr.ACE2 receptor expression and severe acute respiratory" exact="syndrome" post="coronavirus infection depend on differentiation of human airway epithelia."/>
 <result pre="PerlmanS, McCrayPBJr.ACE2 receptor expression and severe acute respiratory syndrome coronavirus" exact="infection" post="depend on differentiation of human airway epithelia. J Virol2005;79:14614â€&quot;14621.16282461"/>
 <result pre="PenningerJM.Multiple functions of angiotensin-converting enzyme 2 and its relevance in" exact="cardiovascular" post="diseases. Circ J2013;77:301â€&quot;308.23328447 18NatarajC, OliverioMI, MannonRB, MannonPJ, AudolyLP, AmuchasteguiCS,"/>
 <result pre="lymphocytes. Mol Immunol2011;48:1835â€&quot;1843.21641648 21ChannappanavarR, ZhaoJ, PerlmanS.T cell-mediated immune response to" exact="respiratory" post="coronaviruses. Immunol Res2014;59:118â€&quot;128.24845462 22AliQ, WuY, HussainT.Chronic AT2 receptor activation"/>
 <result pre="AT1 receptor function and blood pressure in obese Zucker rats." exact="Kidney" post="Int2013;84:931â€&quot;939.23823602 23WhiteJM, WhittakerGR.Fusion of enveloped viruses in endosomes. Traffic2016;17:593â€&quot;614.26935856"/>
 <result pre="KengCT, TanYJ, MirazimiA.Dual effect of nitric oxide on SARS-CoV replication:" exact="viral" post="RNA production and palmitoylation of the S protein are"/>
 <result pre="functions. Ann Rheum Dis2006;65 Suppl 3:iii37â€&quot;iii40.17038470 27SafariT, NematbakhshM.Role of angiotensin" exact="type 2" post="receptor on nitric oxide production response to angiotensin II"/>
 <result pre="apoptosis of COS-1 mediated by the mitochondrial pathway. Artif Cells" exact="Blood" post="Substit Immobil Biotechnol2007;35:237â€&quot;253.17453707 29BeckmanJS, KoppenolWH.Nitric oxide, superoxide, and peroxynitrite:"/>
 <result pre="ShangY.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
 <result pre="Lancet Respir Med2020;8:475â€&quot;481.32105632 34FanelliV, FiorentinoM, CantaluppiV, GesualdoL, StalloneG, RoncoC, CastellanoG.Acute" exact="kidney injury" post="in SARS-CoV-2 infected patients. Crit Care2020;24:155.32299479 35TangN, BaiH, ChenX,"/>
 <result pre="SunZ.Anticoagulant treatment is associated with decreased mortality in severe coronavirus" exact="disease" post="2019 patients with coagulopathy. J Thromb Haemost2020;18:1094â€&quot;1099.32220112 36WangF, XiaZF,"/>
 <result pre="ChenXL, JiaYT, WangYJ, MaB.Angiotensin II type-1 receptor antagonist attenuates LPS-induced" exact="acute" post="lung injury. Cytokine2009;48:246â€&quot;253.19748795 37PhadkeM, SaunikS.Rapid response: Use of angiotensin"/>
 <result pre="KsiazekTG, SeidahNG, NicholST.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J2005;2:69.16115318 42KhanA, BenthinC, ZenoB, AlbertsonTE, BoydJ,"/>
 <result pre="pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in" exact="acute" post="respiratory distress syndrome. Crit Care2017;21:234.28877748 43HaschkeM, SchusterM, PoglitschM, LoibnerH,"/>
 <result pre="clinical trial of recombinant human angiotensin-converting enzyme 2 in acute" exact="respiratory" post="distress syndrome. Crit Care2017;21:234.28877748 43HaschkeM, SchusterM, PoglitschM, LoibnerH, SalzbergM,"/>
 <result pre="and angiotensin II receptor blockers with mortality among patients with" exact="hypertension" post="hospitalized with COVID-19. Circ Res2020;doi: 10.1161/CIRCRESAHA.120.317134."/>
</results>
